News
Enrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expected in 2H2026Attack dataset continues to accumulate in RAPIDe-3, a pivotal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback